This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
by Zacks Equity Research
IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
by Zacks Equity Research
BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
by Ekta Bagri
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates with blockbuster potential.
Intellia Crashes 60% in a Year: How Should You Play the Stock?
by Ekta Bagri
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
by Zacks Equity Research
The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
by Zacks Equity Research
The mean of analysts' price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study
by Zacks Equity Research
Lilly's muvalaplin significantly reduces elevated Lp(a) levels compared to placebo in a phase II study
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
by Zacks Equity Research
IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.
Company News for Nov 7, 2024
by Zacks Equity Research
Companies in The News Are: ODP,IONS,JCI,QLYS
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 18.10% and 3.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?
by Zacks Equity Research
Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.
Viatris to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
VTRS' Q3 results are likely to gain from new product launches in all major geographies.
Gilead Science to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports third-quarter 2024 results.